Umbilical cord blood-derived cellular allograft finds potential applications in bone regeneration

New research has demonstrated that cytokines in an umbilical cord blood-derived product stimulate cellular processes important for bone regeneration.

Go to the profile of Regenerative Medicine
Oct 23, 2018
0
0

The study demonstrates that a uniquely processed umbilical cord blood product (UCBp) supports proliferation and migration of mesenchymal stem cells (MSCs) and stimulates secretion of factors that promote osteogenic differentiation and neovascularization. These processes are crucial for bone regeneration, suggesting that processed allografts from UCB could have applications in orthopedic treatments like spinal fusions and bone nonunion.

UCBp from 33 donors were profiled in this study to identify and quantify 44 different cytokines, which account for the pro-proliferative, pro-migratory, pro-angiogenic and pro-secretory potential of the UCBp. UCBp induced secretion of VEGF-A by MSCs to enhance angiogenesis in endothelial cells, which illustrates regulation of cellular cross-talk by UCBp. Similarly, UCBp impacted osteogenic differentiation of MSCs by upregulating the secretion of osteoprotegerin.

Bone repair can be a challenging procedure, especially in patients with compromised health. Intensive research using MSC-based cytotherapy has shown promise in orthopedic complications. Cytokines secreted by the MSCs are most likely the primary players that orchestrate cellular functions of the residing host cells to partake in tissue regeneration. The study not only highlights the critical role of cytokines in UCB, but also underpins the importance of processing technique used to preserve its unique molecular heterogeneity in the final clinical product for a positive regenerative outcome.  

Read their Open Access article to find out more. 

Mustafi SB. Cytokines in umbilical cord blood-derived cellular product: a mechanistic insight into bone repair. Regen. Med. (2018)(ePub ahead of print)

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.